AXSM Stock Overview
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.94 |
| 52 Week High | US$98.40 |
| 52 Week Low | US$55.02 |
| Beta | 1.1 |
| 1 Month Change | 5.11% |
| 3 Month Change | -19.90% |
| 1 Year Change | -2.30% |
| 3 Year Change | 39.62% |
| 5 Year Change | 250.44% |
| Change since IPO | 768.88% |
Recent News & Updates
Recent updates
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19Axsome Therapeutics: Expect Victory In 2022
Jan 01Axsome: Clarity On Deficiency Letter, I Am Staying Upbeat
Dec 09Axsome Therapeutics: Amid The FDA Difficulty Is A Huge Opportunity
Sep 24Shareholder Returns
| AXSM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.1% | 2.3% | 1.6% |
| 1Y | -2.3% | 10.8% | 25.1% |
Return vs Industry: AXSM underperformed the US Pharmaceuticals industry which returned 9.4% over the past year.
Return vs Market: AXSM underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| AXSM volatility | |
|---|---|
| AXSM Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AXSM's share price has been volatile over the past 3 months.
Volatility Over Time: AXSM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 545 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| AXSM fundamental statistics | |
|---|---|
| Market cap | US$3.61b |
| Earnings (TTM) | -US$296.38m |
| Revenue (TTM) | US$251.02m |
14.4x
P/S Ratio-12.2x
P/E RatioIs AXSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXSM income statement (TTM) | |
|---|---|
| Revenue | US$251.02m |
| Cost of Revenue | US$24.81m |
| Gross Profit | US$226.22m |
| Other Expenses | US$522.59m |
| Earnings | -US$296.38m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.24 |
| Gross Margin | 90.12% |
| Net Profit Margin | -118.07% |
| Debt/Equity Ratio | 124.1% |
How did AXSM perform over the long term?
See historical performance and comparison